AvailableEXPANDED_ACCESS

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

At a glance

Status

Available

Sponsor

Takeda

What is this study about?

As the HGT-HIT-046 (NCT01506141) and SHP609-302 (NCT02412787) studies are completed and closed, this post-trial access (PTA) program provides TAK-609 to participants in these studies for whom the benefit:risk ratio of continued treatment with idursulfase-IT remains positive.

Who may be eligible?

Age any to any · Sex: MALE

Locations (22)

Phoenix Childrens Hospital
Phoenix, United States· Available
The Regents of the University of California
Oakland, United States· Available
The Nemours Foundation
Wilmington, United States· Available
Jackson Memorial Hospital University of Miami
Miami, United States· Available
Ann and Robert H Lurie Childrens Hospital of Chicago
Chicago, United States· Available
Washington University
Washington, United States· Available
Board of Regents of the University of Nebraska
Omaha, United States· Available
Joseph M. Sanzari Children's Hospital
Hackensack, United States· Available
NYU Langone Medical Center
New York, United States· Available
The University of North Carolina
Chapel Hill, United States· Available
The Cleveland Clinic Foundation
Cleveland, United States· Available
Randall Children's Hospital at Legacy Emanuel
Portland, United States· Available

+10 more sites — see the official record for the full list.

How to find out more

Takeda Contact

medinfoUS@takeda.com +1877-825-3327 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.